Chinese expert consensus on drug interaction management of poly ADP-ribose polymerase inhibitors.
10.3760/cma.j.cn112152-20221223-00849
- Collective Name:Branch of Oncology Pharmacists of Chinese Pharmacist Association;Committee of Clinical Pharmacy on Oncology of China Anticancer Association;Committee of Clinical Pharmacy on Oncology of Zhejiang Anticancer Association;Committee of Antineoplastic Drugs of Zhejiang Pharmaceutical Association;Committee of Zhejiang Evidence-based Pharmacy Association
- Publication Type:Journal Article
- Keywords:
Drug interactions;
Expert consensus;
Neoplasms;
Poly ADP-ribose polymerase inhibitors
- MeSH:
Male;
Female;
Humans;
Poly(ADP-ribose) Polymerase Inhibitors/pharmacology*;
Consensus;
Ovarian Neoplasms/drug therapy*;
Drug Interactions;
Adenosine Diphosphate Ribose/therapeutic use*
- From:
Chinese Journal of Oncology
2023;45(7):584-593
- CountryChina
- Language:Chinese
-
Abstract:
Poly ADP-ribose polymerase inhibitors (PARPi), which approved in recent years, are recommended for ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and other cancers by The National Comprehensive Cancer Network (NCCN) and Chinese Society of Clinical Oncology (CSCO) guidelines. Because most of PARPi are metabolized by cytochrome P450 enzyme system, there are extensive interactions with other drugs commonly used in cancer patients. By setting up a consensus working group including pharmaceutical experts, clinical experts and methodology experts, this paper forms a consensus according to the following steps: determine clinical problems, data retrieval and evaluation, Delphi method to form recommendations, finally formation expert opinion on PARPi interaction management. This paper will provide practical reference for clinical medical staff.
